LA
NKTR icon

Lee Ainslie’s Nektar Therapeutics NKTR Stock Holding History

Lee Ainslie’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-214,559
Closed -$12.2M – 369
2022
Q2 		$12.2M Sell
214,559
-104,969
-33% -$6.62M 0.3% 49
2022
Q1 		$25.8M Sell
319,528
-68,646
-18% -$10.2M 0.45% 47
2021
Q4 		$78.7M Sell
388,174
-1,054
-0.3% -$229K 0.89% 27
2021
Q3 		$105M Buy
389,228
+5,156
+1% +$1.24M 1.06% 24
2021
Q2 		$98.9M Sell
384,072
-6,482
-2% -$1.79M 0.93% 22
2021
Q1 		$117M Sell
390,554
-53,154
-12% -$16.5M 1.08% 17
2020
Q4 		$113M Buy
443,708
+65,160
+17% +$16.8M 1.81% 21
2020
Q3 		$94.2M Buy
378,548
+32,772
+9% +$10.3M 1.75% 19
2020
Q2 		$120M Buy
345,776
+19,216
+6% +$6M 2.53% 13
2020
Q1 		$87.4M Buy
326,560
+110,478
+51% +$34.2M 1.85% 15
2019
Q4 		$70M Buy
+216,082
New +$62.7M 1.02% 22

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Lee Ainslie's NKTR Position: Q3 2022 in Review

Lee Ainslie sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 214,559 shares — an estimated $12.2M sold.

Lee Ainslie first reported a position in NKTR in Q4 2019 and held it in 11 quarters. The position peaked at $120M in Q2 2020. 231 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

  • Lee Ainslie reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Lee Ainslie sold 214,559 Nektar Therapeutics shares in Q3 2022, an estimated $12.2M.
  • Lee Ainslie first reported a position in Nektar Therapeutics in Q4 2019 and held it in 11 quarters.
  • Lee Ainslie's Nektar Therapeutics position peaked at $120M in Q2 2020.
  • 231 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Maverick Capital's 13F filing for Q3 2022, filed 14 Nov 2022.